$57.94
0.380.66%
Last update: 2:11 PM
15 minutes delayed
Ultragenyx Pharmaceutical reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Ultragenyx Pharmaceutical using advanced sorting and filters.
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Jun 2024 | 2024-08-01 | $-1.52 | $-1.72 | 11.6 % |
Mar 2024 | 2024-05-02 | $-2.03 | $-1.76 | -15.3 % |
Dec 2023 | 2024-02-15 | $-1.52 | $-1.62 | 6.17 % |
Sep 2023 | 2023-11-02 | $-2.23 | $-2.06 | -8.25 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Jun 2024 | 2024-08-01 | $147.03M | $123.18M | 19.4 % |
Mar 2024 | 2024-05-02 | $108.83M | $116.17M | -6.32 % |
Dec 2023 | 2024-02-15 | $127.39M | $119.38M | 6.71 % |
Sep 2023 | 2023-11-02 | $98.05M | $110.02M | -10.9 % |
Ultragenyx Pharmaceutical (RARE) is scheduled to report earnings on October 31, 2024. The last reported earnings were for reported on August 1, 2024 for Q2.
The Actual EPS was $-1.52, which beat the estimate of $-1.72.
The Actual Revenue was $147M, which beat the estimate of $123.2M.
Browse earnings estimates, EPS, and revenue on all stocks.